Elanco Animal Health (ELAN) Stock Price, News & Analysis

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ELAN shares.
View ELAN analyst ratings or view top-rated stocks.

7 brokerages have issued twelve-month price objectives for Elanco Animal Health's stock. Their ELAN share price targets range from $12.00 to $20.00. On average, they anticipate the company's stock price to reach $16.71 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price.
View analysts price targets for ELAN or view top-rated stocks among Wall Street analysts.

Elanco Animal Health's stock was trading at $14.90 at the start of the year. Since then, ELAN shares have decreased by 6.9% and is now trading at $13.87.
View the best growth stocks for 2024 here.

Elanco Animal Health saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 12,980,000 shares, a decrease of 5.2% from the February 29th total of 13,690,000 shares. Based on an average daily trading volume, of 4,340,000 shares, the days-to-cover ratio is presently 3.0 days.
View Elanco Animal Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ELAN earnings forecast.

Elanco Animal Health Incorporated (NYSE:ELAN) announced its quarterly earnings results on Monday, February, 26th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by $0.02. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive trailing twelve-month return on equity of 6.44%. Elanco Animal Health's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.19 EPS.

ETFs with the largest weight of Elanco Animal Health (NYSE:ELAN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), First Trust Health Care AlphaDEX Fund (FXH), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), Principal Healthcare Innovators ETF (BTEC), VanEck Agribusiness ETF (MOO) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Elanco Animal Health issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 0.870-0.950 for the period, compared to the consensus estimate of 0.890. The company issued revenue guidance of $4.5 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion.

169 employees have rated Elanco Animal Health Chief Executive Officer Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), Walt Disney (DIS), Johnson & Johnson (JNJ), AT&T (T), Cisco Systems (CSCO), CVS Health (CVS) and Bristol-Myers Squibb (BMY).

Elanco Animal Health (ELAN) raised $1.4 billion in an IPO on Thursday, September 20th 2018. The company issued 62,900,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Elanco Animal Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.79%), Perpetual Ltd (0.21%), Sanders Morris Harris LLC (0.08%) and Mcdonald Partners LLC (0.00%). Insiders that own company stock include Art A Garcia, Elanco Animal Health Inc, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, R David Hoover and Rajeev A Modi.
View institutional ownership trends.

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.